26,996 Shares in Castle Biosciences, Inc. $CSTL Acquired by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC bought a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 26,996 shares of the company’s stock, valued at approximately $615,000. Campbell & CO Investment Adviser LLC owned about 0.09% of Castle Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of CSTL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares during the period. Envestnet Asset Management Inc. boosted its position in Castle Biosciences by 1.0% in the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock worth $1,439,000 after purchasing an additional 707 shares during the last quarter. Inspire Investing LLC grew its stake in shares of Castle Biosciences by 4.0% during the 3rd quarter. Inspire Investing LLC now owns 19,887 shares of the company’s stock valued at $453,000 after purchasing an additional 770 shares during the period. CWM LLC grew its stake in shares of Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after purchasing an additional 853 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after purchasing an additional 1,391 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Kristen M. Oelschlager sold 14,888 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $39.31, for a total value of $585,247.28. Following the transaction, the chief operating officer owned 12,323 shares of the company’s stock, valued at approximately $484,417.13. The trade was a 54.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Derek J. Maetzold sold 1,339 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $40.10, for a total transaction of $53,693.90. Following the transaction, the insider directly owned 29,513 shares of the company’s stock, valued at $1,183,471.30. The trade was a 4.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,442 shares of company stock worth $1,826,797 over the last quarter. Insiders own 6.50% of the company’s stock.

Wall Street Analysts Forecast Growth

CSTL has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Lake Street Capital lifted their price target on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 2nd. Canaccord Genuity Group raised their target price on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Finally, Robert W. Baird lifted their target price on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research report on Tuesday, November 4th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $46.00.

Castle Biosciences Trading Up 0.3%

Shares of Castle Biosciences stock opened at $40.98 on Thursday. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $42.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. The company has a market capitalization of $1.20 billion, a P/E ratio of -91.07 and a beta of 1.06. The company has a fifty day moving average of $38.86 and a 200 day moving average of $28.02.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. The business had revenue of $80.55 million for the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. On average, sell-side analysts anticipate that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.